Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade D 9.16 -2.03% -0.19
VNDA closed down 2.03 percent on Friday, March 27, 2020, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical VNDA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish -2.03%
1,2,3 Retracement Bearish Bearish Swing Setup -2.03%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.03%
Wide Bands Range Expansion -2.03%
Up 3 Days in a Row Strength -2.03%
MACD Bullish Signal Line Cross Bullish -0.97%
Wide Bands Range Expansion -0.97%
Calm After Storm Range Contraction 3.74%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.
Biopharmaceutical Chemical Compounds Organic Compounds Oncology Chemotherapy Schizophrenia Central Nervous System Disorders Major Depressive Disorder Depression Pyridines Nausea Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Pruritus Vomiting Sedatives Fanapt Iloperidone Insomnia

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.98
52 Week Low 7.12
Average Volume 736,259
200-Day Moving Average 13.90
50-Day Moving Average 11.78
20-Day Moving Average 9.60
10-Day Moving Average 8.49
Average True Range 0.99
ADX 41.28
+DI 19.87
-DI 27.61
Chandelier Exit (Long, 3 ATRs ) 8.56
Chandelier Exit (Short, 3 ATRs ) 10.09
Upper Bollinger Band 12.05
Lower Bollinger Band 7.15
Percent B (%b) 0.41
BandWidth 51.04
MACD Line -0.91
MACD Signal Line -1.06
MACD Histogram 0.154
Fundamentals Value
Market Cap 410.9 Million
Num Shares 44.9 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -39.83
Price-to-Sales 4.05
Price-to-Book 4.81
PEG Ratio -2.09
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.18
Resistance 3 (R3) 10.13 9.73 10.01
Resistance 2 (R2) 9.73 9.47 9.76 9.95
Resistance 1 (R1) 9.45 9.31 9.59 9.50 9.90
Pivot Point 9.05 9.05 9.13 9.08 9.05
Support 1 (S1) 8.77 8.79 8.91 8.82 8.42
Support 2 (S2) 8.37 8.63 8.40 8.37
Support 3 (S3) 8.09 8.37 8.31
Support 4 (S4) 8.14